Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations

Atara Biotherapeutics, Inc. (ATRA)

7.31   -0.04 (-0.54%) 06-26 21:38
Open: 7.4 Pre. Close: 7.35
High: 7.68 Low: 7.1
Volume: 2,360,013 Market Cap: 683(M)
Atara Biotherapeutics, Inc., an off-the-shelf T-cell immunotherapy company, develops treatments for patients with cancer, autoimmune, and viral diseases in the United States. It is developing tabelecleucel, a T-cell immunotherapy that is Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as hematologic and solid tumors, including nasopharyngeal carcinoma. The company is also developing next-generation CAR T immunotherapies for patients with hematologic malignancies and solid tumors, including ATA2271 and ATA3271 for mesothelin; and ATA2431 and ATA3219 for B-cell malignancies, as well as ATA188 for the treatment of multiple sclerosis. In addition, it develops ATA368 program for patients with human papillomavirus associated cancers. Atara Biotherapeutics, Inc. has a license agreement with Memorial Sloan Kettering Cancer Center; license, and research and development collaboration agreement with QIMR Berghofer Medical Research Institute; and strategic collaboration with H. Lee Moffitt Cancer Center, as well as Bayer AG for mesothelin-targeted CAR T-cell therapies for solid tumors. The company was incorporated in 2012 and is headquartered in South San Francisco, California.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 7.68 - 7.72 7.72 - 7.75
Low: 7.01 - 7.05 7.05 - 7.08
Close: 7.25 - 7.31 7.31 - 7.36

Technical analysis

as of: 2022-06-24 4:38:10 PM
Stoxline posted a BUY today, same as yesterday. Upward movement continues.
Target: Six months: 8.97     One year: 10.47
Support: Support1: 5.78    Support2: 4.61
Resistance: Resistance1: 7.67    Resistance2: 8.97
Pivot: 5.87
Moving Average: MA(5): 6.75     MA(20): 5.66
MA(100): 8.42     MA(250): 12.69
MACD: MACD(12,26): 0.2     Signal(9): -0.1
Stochastic oscillator: %K(14,3): 92     %D(3): 91.3
RSI: RSI(14): 67.3
52-week: High: 20.04  Low: 4.61
Average Vol(K): 3-Month: 1,138 (K)  10-Days: 1,520 (K)

Price, moving averages and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.
[ ATRA ] has closed below upper band by 1.9%. Bollinger Bands are 8.4% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Headline News

Fri, 24 Jun 2022
Is Atara Biotherapeutics Inc (ATRA) a Leader in the Healthcare Sector? - InvestorsObserver

Thu, 23 Jun 2022
Building Revolutionary Solidarity Across the Americas Against the Failed “Summit of the Americas” – Liberation News - Liberation

Wed, 22 Jun 2022
Bloomberg-Funded AGs Push Climate Cases Targeting Domestic Energy Producers – InsideSources - InsideSources

Fri, 17 Jun 2022
Will Business Expansion Plans Aid FEMSA's (FMX) Stock Growth? - Yahoo Finance

Fri, 17 Jun 2022
Atara Biotherapeutics (NASDAQ:ATRA) Shares Gap Up to $5.05 - Defense World

Fri, 10 Jun 2022
Inhibition of myeloid-derived suppressive cell function with all-trans retinoic acid enhanced anti-PD-L1 efficacy in cervical cancer | Scientific Reports -

Financial Analysis

Price to Book Value: Outperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Underperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Underperform
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Underperform
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Outperform
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. 0 (M)
Shares Float 90 (M)
% Held by Insiders 6.991e+007 (%)
% Held by Institutions 0.5 (%)
Shares Short 9,730 (K)
Shares Short P.Month 0 (K)

Stock Financials

EPS -3.3103e+008
EPS Est Next Qtl -1.08
EPS Est This Year -3.92
EPS Est Next Year -4.37
Book Value (p.s.) 0
Profit Margin (%) 0
Operating Margin (%) -1
Return on Assets (ttm) 673.8
Return on Equity (ttm) -40.3
Qtrly Rev. Growth 2.034e+007
Gross Profit (p.s.) 0
Sales Per Share -50.66
EBITDA (p.s.) 1.12376e+007
Qtrly Earnings Growth -3.7
Operating Cash Flow 0 (M)
Levered Free Cash Flow -221 (M)

Stock Valuations

PE Ratio -0.01
PEG Ratio 0
Price to Book value 0
Price to Sales -0.15
Price to Cash Flow 3.76

Stock Dividends

Dividend 0
Forward Dividend 1.179e+007
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
7 Binary Options
Your Ad Here
StockChart iOS
StoxlineLite iOS
StoxlineLite iOS
OptionCalc iOS
StockChart Android
StoxlineLite Android
StoxlinePro Android
OptionCalc Android
(c) 2006-2022 | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the web site, a user agrees not to redistribute the information found therein.